Vitamin D differentially modulates effector and regulatory T-cell migration across the blood-brain barrier

Authors:
  • SSSasha Soldati
    Sasha Soldati
  • ABAlexander Bar
    Alexander Bar
  • FBFelix Blumer
    Felix Blumer
  • APArindam Pal
    Arindam Pal
  • SKSaniya Kari
    Saniya Kari
  • MVMykhailo Vladymyrov
    Mykhailo Vladymyrov
  • ADAhmad Danial
    Ahmad Danial
  • JKJustin Killick
    Justin Killick
  • AMAdrien Mossu
    Adrien Mossu
  • EBElisa Bouillet
    Elisa Bouillet
  • SBSara Barcos
    Sara Barcos

Abstract
Multiple sclerosis (MS) is an inflammatory disease of the CNS influenced by a combination of genetic predisposition and environmental factors. Vitamin D (VitD) deficiency is considered a major risk factor for MS. While VitD is associated with immunomodulatory roles, the exact mechanisms by which VitD protects from disease are still largely unknown. CD4 T cells play a key role in MS pathogenesis with autoimmune effector T cells (Teff) infiltrating the CNS across the blood-brain barrier (BBB) and regulatory T cells (Treg) displaying impaired functions. Here we show that treatment of human CD4 T cells with the active form of VitD (1,25-Dihydroxyvitamin D3; 1,25(OH)2D3) decreased cell-surface expression of α4β1- and αLβ2-integrins on Teff but not Treg and reduced Teff adhesion to their endothelial ligands VCAM-1 and ICAM-1. By employing live cell imaging, we observed that VitD treatment reduced arrest of Teff but not Treg to the BBB as well as ICAM-1 and VCAM-1 under physiological flow in vitro and differentially affected post-arrest behaviour of Teff versus Treg on the BBB under physiological flow. Furthermore, VitD treatment favoured the migration of Treg over Teff across the BBB under static and flow conditions in vitro. In vivo live cell imaging showed that VitD reduced T cell arrest on the inflamed BBB during autoimmune neuroinflammation. Finally, VitD also reduced expression of integrins mediating CNS homing on pathogenic CD4 T cells isolated from the CSF of persons with MS (PwMS). As VitD treatment did not alter barrier properties or adhesion molecule profile of our BBB model we propose a beneficial effect of VitD supplementation in PwMS by reducing CNS trafficking of pro-inflammatory T cells while leaving CNS entry of Treg unaffected.
Funding Information
  • Swiss National Science Foundation (310030E_189312)
  • Swiss National Science Foundation (CRSII3_154483)
  • Swiss MS Society
  • European Research Council (ERC-2013-ADG 340733)
  • Agence Nationale de la Recherche (ANR-19-CE14-0043)
  • Foundation France SEP
  • Multiple Sclerosis Society (859/07)
  • Multiple Sclerosis Society (41)
  • Eugène Devic EDMUS Foundation
  • Fondation d'Aide pour la Recherche sur la Sclerose en Plaques
  • Hubert Curien/germaine de Stael
  • Bangerter Rhyner Foundation
  • Edinburgh Neuroscience funds
  • European Committee for Treatment and Research in Multiple Sclerosis